Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metablok - Arch Biopartners

Drug Profile

Metablok - Arch Biopartners

Alternative Names: LSALT peptide; MetaBlok

Latest Information Update: 25 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arch Biopartners; University of Calgary
  • Developer Arch Biopartners; Sunnybrook Health Sciences Centre; University of Calgary
  • Class Peptides
  • Mechanism of Action Dipeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute kidney injury; COVID 2019 infections; SARS-CoV-2 acute respiratory disease
  • No development reported Cancer metastases; Sepsis

Most Recent Events

  • 15 Mar 2024 Arch Biopartners initiates enrollment in phase II CS-AKI trial for Acute kidney injury (Prevention) in Canada (IV, Injection)
  • 08 Mar 2024 Arch Biopartners initiates enrollment in a phase II CS-AKI trial for Acute kidney injury (Prevention) in Turkey (IV, Injection)(NCT05879432)
  • 10 Jan 2024 Arch Biopartners plans a phase II trial for Acute kidney injury (Prevention) in USA, Canada and Turkey (IV, Injection) in February 2024 (NCT05879432)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top